The efficacy of photodynamic therapy (PDT) has been hindered by the severe hypoxia prevalent in solid tumors and the aggregation-caused quenching effect observed with conventional photosensitizers (PSs). PSs featuring type I reactive oxygen species (ROS) and aggregation-induced emission (AIE) activity offer promising solutions to these challenges. Here, type I AIE photosensitizer that hardly consume oxygen during PDT was synthesized, nanocarriers was used to deliver the photosensitizer to tumor, the results showed that the new photosensitizer can enhance the therapeutic efficacy. Furthermore, our results also demonstrated that the measurement of photosensitizer and oxygen with multispectral method during PDT is useful for efficacy assessment, which can be introduced to endoscope and other clinic applications, such as port wine stains PDT treatment. Port wine stains with PDT treatment has a good outcome, especially for children. However, the pricking and burning sensation during photodynamic therapy is very acute, which is hard to bear for children and limit the efficiency. Also, an in situ anaesthesia strategies was developed, in which a nanostructure was designed to encapsulate the photosensitizer and lidocaine for medicine delivery and in situ releasing, electrophysiology technology assessment showed it a good outcome with pain relief.